428 related articles for article (PubMed ID: 31663736)
41. Computational predictions of corroles as a class of Hsp90 inhibitors.
Teo RD; Dong SS; Gross Z; Gray HB; Goddard WA
Mol Biosyst; 2015 Nov; 11(11):2907-14. PubMed ID: 26252737
[TBL] [Abstract][Full Text] [Related]
42. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
43. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
44. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
45. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
[TBL] [Abstract][Full Text] [Related]
46. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response.
McConnell JR; Alexander LA; McAlpine SR
Bioorg Med Chem Lett; 2014 Jan; 24(2):661-6. PubMed ID: 24360559
[TBL] [Abstract][Full Text] [Related]
47. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
48. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
Kitson RR; Moody CJ
Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
[TBL] [Abstract][Full Text] [Related]
49. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
50. Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases.
Tukaj S; Zillikens D; Kasperkiewicz M
Exp Dermatol; 2015 Aug; 24(8):567-71. PubMed ID: 25980533
[TBL] [Abstract][Full Text] [Related]
51. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
[TBL] [Abstract][Full Text] [Related]
52. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
Wang Y; McAlpine SR
Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
[TBL] [Abstract][Full Text] [Related]
53. Organelle-specific Hsp90 inhibitors.
Seo YH
Arch Pharm Res; 2015 Sep; 38(9):1582-90. PubMed ID: 26195286
[TBL] [Abstract][Full Text] [Related]
54. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
[TBL] [Abstract][Full Text] [Related]
55. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
57. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
58. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
59. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
Blagg BS; Kerr TD
Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
[TBL] [Abstract][Full Text] [Related]
60. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
